Answers are grounded in this paper and cite their sources.
The search for novel phosphodiesterase Type 4 (PDE4) inhibitors is currently one of the most active fields within the pharmaceutical industry. Recent progress in the clinical development of PDE4 inhibitors is reviewed. Particular emphasis is placed on those patents published within the past two years, highlighting the novel structural classes of PDE4 inhibitors reported.
No takes yet. Share an insight, caveat, or question.
Peter Norman (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: